Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-12-18 00:00:00 ET · period of report 2024-12-16 · accession 0001649094-24-000124 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-18 | 2024-12-16 | PCVX | Cowan Elvia | SVP, Fin | M - OptEx | $25.92 | +7,716 | 19.3K | +67% | +$200.0K |
| D | 2024-12-18 | 2024-12-16 | PCVX | Cowan Elvia | SVP, Fin | M - OptEx | $0.00 | -7,716 | 106.3K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-16 | M | A | 7,716 | $25.92 | 19,294 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-12-16 | M | D | 7,716 | $0.00 | 106,284 | D | $25.92 · — to 2032-08-08 | 7,716 Common Stock | (F1) 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |